A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)

BACKGROUND: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Gynecol Oncol
Hauptverfasser: Lee, Yong Jae, Lim, Myong Cheol, Kim, Byoung-Gie, Ngoi, Natalie YL, Choi, Chel Hun, Park, Sang-Yoon, Tan, David SP, Go, Yunjung, Lee, Jung-Yun
Format: Artigo
Sprache:Inglês
Veröffentlicht: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2021
Schlagworte:
Clinical Trial Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930449/
https://ncbi.nlm.nih.gov/pubmed/33559413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3802/jgo.2021.32.e31
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge